https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-302012-08-01 00:00:002019-02-15 09:21:33Newcastle disease virus: a promising agent for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-912012-08-01 00:00:002012-08-01 00:00:00Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-612012-07-31 00:00:002019-02-15 08:39:15Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-27 / Int J Hyperthermia 2012;28(7):597-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-27 / Int J Hyperthermia 2012;28(7):597-6042012-07-27 00:00:002012-07-27 00:00:00Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-762012-07-18 00:00:002019-02-15 09:21:29Cell-type-specific innate immune response to oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-222012-07-03 00:00:002019-02-15 09:18:19Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-182012-07-01 00:00:002019-02-15 08:39:54Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-412012-07-01 00:00:002019-02-15 09:21:39Recent clinical experience with oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-332012-07-01 00:00:002019-02-15 09:23:09Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
